撰文丨王聪 编辑丨王多鱼 排版丨水成文 基于干细胞的神经组织工程和脊髓类器官，在 脊髓损伤 （ Spinal Cord Injury， SCI） 的修复方面展现出希望。然而，天然脊髓具有细胞异质性和典型的立体结 构，这使得在类器官结构中重现其特征变得困难，因为这需要包含细胞组成、节段组织和背腹特征的组装。 2025 年 10 月 24 日，同济大学 生命科学与技术学院 朱融融 教授、同济大学附属同济医院 程黎明 教授团队合作 （ 朱颜菁 、 黄蕊奇 、 于立群 为论文共同第 一作者 ） ，在 Nature 子刊 Nature Biomedical Engineering 上发表了题为： Engineered thoracic spinal cord organoids for transplantation after spinal cord injury 的研究论文。 该研究成功构建了 具备胸段脊髓区域异质性和成熟神经回路结构的 工程化胸段脊髓类器官 （engineered thoracic spinal cord organoid，简称为 enTsOrg） ， 移植的 enTsOrg 在因完全脊髓损伤而瘫 ...

Core Insights - The Chinese cell reprogramming industry is rapidly developing and is becoming a significant force in the global cell reprogramming field, with a projected market size of approximately 857 million yuan in 2024, representing a year-on-year growth of 37.78% [1][7] - A breakthrough by Deng Hongkui's team in 2025 will reduce the time required to induce somatic cells into pluripotent stem cells from 30 days to 10 days, while increasing the induction efficiency by 20 times, enhancing the efficiency, quality, and cost-effectiveness of cell preparation for clinical applications [1][7] Industry Overview - Cell reprogramming involves altering gene expression patterns without changing the genetic sequence through epigenetic modifications, transcription factor regulation, or chemical interventions, allowing cells to revert to a pluripotent state [2] - The industry has evolved through three main stages: exploration, breakthrough, and transformation, starting from the 1950s with nuclear transfer research and leading to significant advancements in the 21st century, including the discovery of the OSKM factors and the development of chemical reprogramming techniques [3] Market Size - The Chinese cell reprogramming market is expected to reach approximately 857 million yuan in 2024, with a growth rate of 37.78% compared to the previous year [7][8] Key Companies - Notable companies in the industry include Zhongyuan Xiehe (600645), Nanhua Biological (000504), and Heyuan Biotechnology (688238), among others, which are actively involved in the development and application of cell reprogramming technologies [2][8] Industry Development Trends 1. **Technological Breakthroughs and Clinical Applications**: The rapid chemical reprogramming system developed by Deng Hongkui's team is expected to significantly enhance the development of clinical-grade products such as pancreatic and cardiac cells [10] 2. **Policy Framework and Regulation**: The establishment of a comprehensive policy framework by the national government aims to standardize research and clinical practices, with pilot policies in regions like Hainan and Shenzhen facilitating advanced cell therapy technologies [11][12] 3. **Industry Chain Integration and International Cooperation**: The industry is witnessing increased collaboration across the supply chain, with domestic companies enhancing the localization of key technologies and international partnerships fostering product development and technological exchange [13]